PainReform Ltd. Ordinary Shares
PRFX
PRFX: PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
moreShow PRFX Financials
Recent trades of PRFX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by PRFX's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Depot formulations of a local anesthetic and methods for preparation thereof Feb. 19, 2019
-
Patent Title: Depot formulations of a hydrophobic active ingredient and methods for preparation thereof Dec. 26, 2017
-
Patent Title: Depot formulations of a local anesthetic and methods for preparation thereof Jun. 06, 2017
Federal grants, loans, and purchases
Followers on PRFX's company Twitter account
Number of mentions of PRFX in WallStreetBets Daily Discussion
Recent insights relating to PRFX
Recent picks made for PRFX stock on CNBC
ETFs with the largest estimated holdings in PRFX
Flights by private jets registered to PRFX